Cortex Pharmaceuticals, Inc. to Present at the 14th Annual BIO Investor Forum
October 19 2015 - 8:30AM
Marketwired
Cortex Pharmaceuticals, Inc. to Present at the 14th Annual BIO
Investor Forum
Cortex CEO James S. J. Manuso, Ph.D. to Present
Glen Rock, N.J., October 19, 2015 - Cortex Pharmaceuticals, Inc.
(OTC: CORX) (Cortex or the Company), a leader in developing drugs
for respiratory disorders, particularly obstructive and central
sleep apneas and drug-induced respiratory depression, announces
that it will be presenting at the 14th Annual BIO Investor Forum
(www.bio.org). The conference is being sponsored by the
Biotechnology Industry Organization and is being held on October 20
- 21, 2015 at the Parc 55 Hotel, San Francisco, California. The
Companys CEO, James S. J. Manuso, Ph.D. is scheduled to present at
11:30 a.m. West Coast Time on Tuesday, October 20, 2015.
The conference is attended by public companies, institutional
investors, industry executives, private equity firms, private
companies, venture capitalists, business development executives and
sophisticated private investors.
The presentation will be accessible by live audio webcast at
http://www.veracast.com/webcasts/bio/investorforum2015/48108124757.cfm.
A replay of the live audio webcast will be archived at the same
website address and will be available one hour after the conclusion
of the live event. A copy of the slide presentation to be presented
by the Company is being furnished as an exhibit to a Current Report
on Form 8-K being filed with the U.S. Securities and Exchange
Commission and also will be accessible in the investors section of
the Cortex web-site.
Dr. Manuso will present details of Cortexs clinical initiatives
with respect to dronabinol for obstructive sleep apnea (Phase 2B)
and the Ampakine CX-1739 (oral) for opiate induced respiratory
depression (Phase 2A) and central sleep apnea (Phase 2B).
Additional program and background information will also be
provided.
About Cortex Pharmaceuticals, Inc.
Cortex is a leader in developing drugs for respiratory
disorders, particularly sleep apneas and drug-induced respiratory
depression. The Company owns patents and patent applications for
certain families of chemical compounds that claim the chemical
structures and their use in the treatment of these and other
disorders.
Drug candidates are currently derived from two platforms, as
described below.
The first platform is the class of compounds known as
cannabinoids, in particular, dronabinol. Under a license agreement
with the University of Illinois, the Company has rights to patents
claiming the use of cannabinoids for the treatment of sleep related
breathing disorders. In a double-blind, placebo-controlled,
dose-ascending Phase 2A clinical study conducted by the Company,
dronabinol produced a statistically significant reduction in the
Apnea-Hypopnea Index, the primary therapeutic end-point, and was
observed to be safe and well tolerated in a group of patients with
obstructive sleep apnea (OSA). The University of Illinois and three
other centers currently are investigating dronabinol in a
potentially pivotal, six week, double-blind, placebo-controlled
Phase 2B clinical trial in 120 patients with OSA. This study, which
the University of Illinois expects to be completed during the
second quarter of 2016, is fully funded by the National Heart, Lung
and Blood Institute of the National Institutes of Health. The
Company is not managing or funding this ongoing clinical trial.
The second platform is a class of proprietary compounds known as
ampakines that act to enhance the actions of the excitatory
neurotransmitter glutamate at AMPA glutamate receptors. Several
ampakines in both oral and injectable form are being developed by
Cortex for the treatment of a variety of breathing disorders. In
clinical studies, such drugs have shown preliminary efficacy in
central sleep apnea and in antagonizing respiratory depression
produced by opiates without altering their analgesic effects.
Ampakines also have improved breathing in animal models of orphan
disorders such as Pomp Disease, spinal cord damage and perinatal
respiratory distress. The Companys compounds belong to a new
generation of ampakines that do not display the undesirable side
effects of earlier versions observed in animal models.
Additional information about Cortex and the matters discussed
herein can be obtained on the Companys web-site at
www.cortexpharm.com or in the Companys filings on EDGAR at
www.sec.gov.
Special Note Regarding Forward-Looking Statements: Certain
statements included or incorporated by reference in this news
release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions identify forward-looking statements.
Forward-looking statements include, among other things, statements
regarding future plans, targets, estimates and assumptions.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Many factors could
cause the Company's actual results to differ materially from those
expressed or implied in any forward-looking statements made by, or
on behalf of, the Company. Due to these various risks and
uncertainties, actual events may differ materially from current
expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and,
accordingly, investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Forward-looking statements are made as of the date of this news
release and the Company disclaims any intent or obligation to
update publicly such forward-looking statements, whether as a
result of new information, future events or results or
otherwise.
Company Contact:
Jeff Margolis
Vice-President and Secretary
Telephone: (917) 834-7206
E-mail: jmargolis@cortexpharm.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024